Evidence Table D-9. Continuous delirium severity outcomes for studies comparing interventions to prevent development of delirium

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Mean (SD) delirium severity score, intervention group | Mean (SD) delirium severity score, control group | Mean between-group difference (95% CI) in delirium severity score |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| First-generation antipsychotic vs. placebo  |  |  |  |  |  |  |  |  |
| Kalisvaart, 2005[6](#_ENREF_6) | Acute or elective hip surgery patients, ≥ 70 years, at risk of delirium: MMSE between less than or equal to 24; dehydration=BUN/creatinine> or = to 18, low visual acuity and/or increased severity of illness on APACHE II of 16 or greater. | Haloperidol (Planned dose: 0.5mg), 36 | Placebo (Not applicable), 32 | Oral | DRS-R-98 | 14.4 (3.4) | 18.41 (4.4) | -4.01 (-5.88 to -2.14) |
| Khan, 2018[8](#_ENREF_8) | English speaking individuals undergoing thoracic surgery | Haloperidol (Planned dose: 0.5mg, Planned duration: 4 days (11 doses total)), 68 | Placebo (Planned dose: NR, Planned duration: 4 days (11 doses total)), 67 | Intravenous | DRS-R-98, total population | Baseline: Mean 1.81 (SD 2.11)Final: Mean 1.19 (SD 1.52) | Baseline: Mean 2.9 (SD 4)Final: Mean 1.5 (SD 2.18) | -0.31 (-0.94 to 0.32) |
| Khan, 2018[8](#_ENREF_8) | English speaking individuals undergoing thoracic surgery | Haloperidol (Planned dose: 0.5mg, Planned duration: 4 days (11 doses total)), 7 | Placebo (Planned dose: NR, Planned duration: 4 days (11 doses total)), 17 | Intravenous | DRS-R-98, only patients with delirium | Baseline: Mean 4.1 (SD 3.4)Final: Mean 3 (SD 2.4) | Baseline: Mean 6.5 (SD 6.2)Final: Mean 2.6 (SD 2.8) | 0.4 (-1.69 to 2.49) |
| Schrijver, 2018[12](#_ENREF_12) | Medical and surgical patients | Haloperidol (Planned dose: 1mg), 23 | Placebo, 18 | Oral | Maximum DRS-R-98 score | 15.1 (7.6) | 12.67 (13.5) | 2.43 (-4.27 to 9.14) |

| Author, year | Population | Intervention group, n | Control group, n | Route of administration | Outcome definition | Mean (SD) delirium severity score, intervention group | Mean (SD) delirium severity score, control group | Mean between-group difference (95% CI) in delirium severity score |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  Second-generation antipsychotic vs. placebo |   |   |   |   |   |   |   |   |
| Hakim, 2012[5](#_ENREF_5) | Patients 65 years or older experiencing subsyndromal delirium after on-pump cardiac surgery | Risperidone (Planned dose: 0.5mg), 7 | Placebo (Planned dose: given every 12 hours), 17 | Oral | Highest score on the ICDSC | Median: 6 (IQR 5 to 7) | Median: 5 (IQR 4 to 5) | p=0.234 |
| Larsen, 2010[9](#_ENREF_9) | Post-operative elderly joint replacement surgery patients | Olanzapine (Planned dose: 5mg), 28 | Placebo (Planned dose: 5mg), 82 | Oral | DRS-R-98 | 16.4 (3.7) | 14.5 (2.7) | 1.9 (0.69 to 3.11) |

CI=confidence interval; DRS-R-98= Delirium Rating Scale Revised-98; ICDSC=Intensive Care Delirium Screening Checklist; IQR=interquartile range; mg=milligram; MMSE= Mini-Mental State Examination; p=p-value; SD=standard deviation